Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

BioNTech

Tracked across 10 events · 736 articles · First seen Mar 16, 2026 · Last active Sep 22, 2026

Sentiment
30
Attention
8
Events
10
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -20
Business
Impact: BioNTech, in collaboration with Pfizer, halted a large U.S. trial for their updated COVID-19 vaccine due to low enrollment, potentially impacting future approvals and market share for the 50-64 age group.
Apr 01, 2026 · 6 articles
4 75
Tech
Impact: BioNTech announced positive Phase 2 clinical trial results for trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, in patients with endometrial cancer. This positive development could lead to a biologics license application in 2026 and further clinical trials, potentially increasing its market value and product pipeline.
Apr 11, 2026 · 7 articles
4 70
Tech
Impact: BioNTech is collaborating with Boehringer Ingelheim to evaluate a novel immuno-oncology combination in ES-SCLC. BioNTech will supply pumitamig and retains full rights to its asset.
Apr 09, 2026 · 6 articles
4 75
Regulatory
Impact: BioNTech, a pioneer in mRNA vaccines, is positively impacted by the FDA approval, reinforcing the commercial viability of its mRNA platform.
Aug 06, 2026 · 6 articles
8 20
Accidents
Impact: BioNTech is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
3 -20
Domestic
Impact: BioNTech's COVID-19 vaccine (with Pfizer) may see reduced demand in Germany due to the narrowed recommendations, though uptake was already low.
Jul 13, 2026 · 6 articles
7 30
Regulatory
Impact: BioNTech, a competitor in mRNA vaccines, may be spurred by Moderna's approval to advance its own flu programs.
Aug 05, 2026 · 105 articles
7 70
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: BioNTech is developing a similar personalized cancer vaccine with Roche. The success of Moderna and Merck's trial validates the approach and could boost BioNTech's own pipeline and investor sentiment.
Aug 19, 2026 · 126 articles
1 0
Business
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on RNA medicines, announced on September 22, 2026 the appointment of Monika Vnuk, MD, as Chief Business Officer, a newly created leadership role. Dr.…
Impact: BioNTech is mentioned in connection with the COVID-19 vaccine partnership that Monika Vnuk negotiated while at Pfizer. The event has no direct effect on BioNTech.
Sep 22, 2026 · 6 articles
6 0
Domestic
Mar 16, 2026 · 22 articles
55 BioNTech testing similar treatmentModerna Merck mRNA...
ERGEN INTELLIGENCE
Track BioNTech live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.